AR074505A1 - Vacuna de peptido ch3 de ige. inmunogeno. procedimiento. vector de expresion. celula huesped. - Google Patents
Vacuna de peptido ch3 de ige. inmunogeno. procedimiento. vector de expresion. celula huesped.Info
- Publication number
- AR074505A1 AR074505A1 ARP090104737A ARP090104737A AR074505A1 AR 074505 A1 AR074505 A1 AR 074505A1 AR P090104737 A ARP090104737 A AR P090104737A AR P090104737 A ARP090104737 A AR P090104737A AR 074505 A1 AR074505 A1 AR 074505A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunogen
- group
- composition
- seq
- constituted
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 19
- 238000000034 method Methods 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title 1
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 10
- 230000000890 antigenic effect Effects 0.000 abstract 8
- 239000000203 mixture Substances 0.000 abstract 8
- 239000002245 particle Substances 0.000 abstract 6
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 abstract 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 4
- 235000018417 cysteine Nutrition 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000004971 Cross linker Substances 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 229940037003 alum Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 150000003568 thioethers Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Inmunógenos que comprenden un péptido de IgE antigénico preferentemente unido a un vehículo inmunogénico para la prevención, tratamiento o alivio de trastornos mediados por IgE. Procedimientos para la producción de dichos medicamentos, composiciones inmunogénicas y composición farmacéutica de los mismos y su uso en medicina. Reivindicación 1: Un inmunógeno que comprende al menos un péptico de IgE antigénico unido a un vehículo inmunogénico en el que dicho péptido de IgE antigénico está constituido por una secuencia de aminoácidos seleccionada del grupo constituido por las SEC ID Ns: 312, 311, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332. 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346. 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66. 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159,160, 161,162, 163,164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309 y 310. Reivindicación 5: Un inmunógeno de acuerdo con la reivindicación 1, en el que dicho péptido de IgE antigénico está constituido por una secuencia de aminoácidos seleccionada el grupo constituido por las SEC ID N°: 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332. 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346. 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430. Reivindicación 10: El inmunógeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9, en el que dicho péptido de IgE antigénico comprende además cualquiera de: -en su extremo C-terminal un engarce que tiene la fórmula (G)nC en la que n es un número entero seleccionado del grupo constituido por 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 y 10, preferentemente del grupo constituido por 0, 1, 2, 3, 4, y 5, más preferentemente de los grupos constituidos por 0, 1, 2 y 3, más preferentemente n es 0 o 1 (cuando n es igual a 0 dicha fórmula representa una cisteína) o, -en su extremo N-terminal un engarce que tiene la fórmula C(G)n, en la que n es un número entero seleccionado del grupo constituido por 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 y 10, preferentemente del grupo constituido por 0, 1, 2. 3, 4 y 5, más preferentemente de los grupos constituidos por 0, 1, 2 y 3, más preferentemente n es 0 o 1 (cuando n es igual a 0 la fórmula representa una cisteína) o, -en su extremo C-terminal un engarce que tiene la fórmula (G)nC, en la que si n es un número entero seleccionado del grupo constituido por 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 y 10, preferentemente del grupo constituido por 0, 1, 2, 3, 4 y 5, más preferentemente de los grupos constituidos por 0, 1, 2 y 3, más referentemente n es 0 o 1 (cuando n es igual a 0 dicha fórmula representa una cisteína) y en su extremo N-terminal un engarce que tiene la fórmula C(G)n, en la que n es un número entero seleccionado del grupo constituido por 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 y 10, preferentemente del grupo constituido por 0, 1, 2, 3, 4 y 5 más preferentemente por los grupos constituidos por 0, 1, 2 y 3, más preferentemente n es 0 o 1 (cuando n es igual a 0 la fórmula representa una cisteína). Reivindicación 11: El inmunógeno de acuerdo con una cualquiera de las reivindicaciones 1 a 10, en el que dicho vehículo inmunogénico es una partícula similar a virus seleccionada del grupo constituido por VLP de HBcAg, HBsAg y Qbeta. Reivindicación 14: Una composición que comprende al menos dos inmunógenos de acuerdo con una cualquiera de las reivindicaciones 1 a 13. Reivindicación 97: Una composición que comprende dos inmunógenos, estando constituido cada uno de estos inmunógenos por un péptido de IgE antigénico conjugado individualmente con una partícula similar a virus de Qbeta en la que: el primer inmunógeno está constituido por un péptido de IgE antigénico de la SEC ID N°: 220 entrecruzado químicamente con una partícula similar a virus de Qbeta de la SEC ID N°: 435 mediante un enlace tioéter usando SMPH (Succinimidil-6-[beta-maleimidopropionamido]hexanoato) como entrecruzante, siendo dicho enlace entre un resto de lisina de la partícula similar a virus y el resto de cisteína de dicho péptido de IgE antigénico y; el segundo inmunógeno está constituido por un polipéptido de la SEC ID N°: 457 entrecruzado químicamente con una partícula similar a virus de Qbeta de la SEC ID N°: 435 mediante un enlace tioéter usando SMPH(Succinimidil-6-[beta-maleimidopropionamido]hexanoato) como entrecruzante, siendo dicho enlace entre un resto de lisina de la partícula similar a virus y el resto de cisteína de dicho polipéptido. Reivindicación 101: Una composición inmunogénica que comprende un inmunógeno de una cualquiera de las reivindicaciones 1 a 13, o una composición de inmunógenos de acuerdo con una cualquiera de las reivindicaciones 14 a 97 que comprende además al menos dos adyuvantes seleccionados del grupo constituido por alumbre, oligonucleótidos que contienen CpG y adyuvantes basados en saponina. Reivindicación 105: El inmunógeno de una cualquiera de las reivindicaciones 1 a 13 o una composición de inmunógenos de acuerdo con una cualquiera de las reivindicaciones 14 a 97, o la composición inmunogénica de una cualquiera de las reivindicaciones 98 a 102 o la composición farmacéutica de la reivindicación 103 para prevenir, aliviar o tratar un trastorno mediado por IgE. Reivindicación 106: El inmunógeno, composición inmunogénica o composición farmacéutica de la reivindicación 105, siendo dicho trastorno mediado por IgE asma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12098908P | 2008-12-09 | 2008-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074505A1 true AR074505A1 (es) | 2011-01-19 |
Family
ID=42035836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104737A AR074505A1 (es) | 2008-12-09 | 2009-12-07 | Vacuna de peptido ch3 de ige. inmunogeno. procedimiento. vector de expresion. celula huesped. |
Country Status (22)
Country | Link |
---|---|
US (3) | US8298547B2 (es) |
EP (2) | EP2865389A1 (es) |
JP (4) | JP5209800B2 (es) |
KR (3) | KR101634058B1 (es) |
CN (1) | CN102245198B (es) |
AR (1) | AR074505A1 (es) |
AU (1) | AU2009325950B2 (es) |
BR (1) | BRPI0922561A2 (es) |
CA (1) | CA2744754A1 (es) |
CO (1) | CO6561830A2 (es) |
DK (1) | DK2376108T3 (es) |
ES (1) | ES2622562T3 (es) |
HK (1) | HK1163511A1 (es) |
IL (1) | IL213029A0 (es) |
MX (2) | MX337723B (es) |
NZ (2) | NZ592977A (es) |
PE (2) | PE20142330A1 (es) |
RU (1) | RU2495049C2 (es) |
SG (2) | SG186611A1 (es) |
TW (1) | TWI387463B (es) |
WO (1) | WO2010067286A2 (es) |
ZA (1) | ZA201104072B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0614366A2 (pt) * | 2005-08-11 | 2009-10-06 | Arpi Matossian Rogers | peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos |
MY160201A (en) | 2008-12-09 | 2017-02-28 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
EP2942061A3 (en) * | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
EP2471926A3 (en) | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
JP5872684B2 (ja) * | 2011-05-26 | 2016-03-01 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
BR112013029966A2 (pt) | 2011-05-26 | 2017-01-31 | Intervet Int Bv | oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, e, vacina para prevenir ou combater uma doença infecciosa |
US9956276B2 (en) | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
JP5918851B2 (ja) * | 2012-06-18 | 2016-05-18 | 日本全薬工業株式会社 | IgEペプチドワクチン |
US20170196952A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
WO2016005545A1 (en) | 2014-07-10 | 2016-01-14 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington's disease |
KR102230325B1 (ko) * | 2015-09-30 | 2021-03-19 | 시오노기 앤드 컴파니, 리미티드 | 면역 부활 활성을 갖는 핵산 유도체 |
KR101876620B1 (ko) * | 2015-10-27 | 2018-07-09 | 대구한의대학교산학협력단 | 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법 |
CN108697779B (zh) | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
MY186779A (en) * | 2017-03-29 | 2021-08-19 | Shionogi & Co | Nucleic acid derivative having immunostimulatory activity |
WO2022058571A1 (en) | 2020-09-17 | 2022-03-24 | Neovacs | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS |
WO2023192203A2 (en) * | 2022-03-28 | 2023-10-05 | The Regents Of The University Of California | Novel plant virus and bacteriophage vaccines |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1980000727A1 (en) | 1978-09-29 | 1980-04-17 | Secretary Energy Brit | Improvements in and relating to electrical power transmission in fluid wells |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
JP2547714B2 (ja) | 1981-10-23 | 1996-10-23 | モルキユラ− バイオシステムズ インコ−ポレテツド | オリゴヌクレオチド治療剤及びその製法 |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
JPS63225397A (ja) * | 1986-10-03 | 1988-09-20 | Dainippon Pharmaceut Co Ltd | 抗アレルギー作用を有する新規ペプチド |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
US5258289A (en) * | 1990-09-05 | 1993-11-02 | Davis Claude G | Method for the selecting of genes encoding catalytic antibodies |
WO1992011291A1 (en) | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
HU219056B (hu) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
WO1996030523A2 (en) | 1995-03-31 | 1996-10-03 | Hans Wolf | Antigen presentation system based on retrovirus-like particles |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
HUP9901109A3 (en) | 1996-03-01 | 1999-11-29 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
ID18046A (id) | 1996-08-20 | 1998-02-19 | Takeda Chemical Industries Ltd | Senyawa siklik campuran, pembuatan dan penngunaannya. |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
JP4101888B2 (ja) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法 |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
CA2320488C (en) | 1998-02-12 | 2007-03-06 | Immune Complex, Corporation | Strategically modified hepatitis b core proteins and their derivatives |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
PL354714A1 (en) | 1998-04-09 | 2004-02-09 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
US7393529B2 (en) * | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
US6734287B1 (en) * | 1998-04-09 | 2004-05-11 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
EP0957111B1 (en) * | 1998-04-09 | 2004-12-29 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
ES2327839T3 (es) | 1998-09-03 | 2009-11-04 | Novartis Vaccines And Diagnostics, Inc. | Monodosis de fgf-2 eficaz angiogenicamente y metodo de uso. |
EP1114024B1 (de) | 1998-09-18 | 2002-11-27 | Pentapharm A.G. | Urokinase-inhibitoren |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
WO2000023955A1 (en) | 1998-10-21 | 2000-04-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Virus-like particles for the induction of autoantibodies |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
ATE315658T1 (de) | 1998-11-05 | 2006-02-15 | Powderject Vaccines Inc | Genkonstrukte für genimmunisierung |
ATE412434T1 (de) | 1998-11-30 | 2008-11-15 | Cytos Biotechnology Ag | Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
US20030170229A1 (en) * | 1999-02-25 | 2003-09-11 | Smithkline Beecham Biologicals S.A. | Vaccine |
MXPA01008612A (es) * | 1999-02-25 | 2003-06-24 | Smithkline Beecham Biolog | Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos. |
CZ303653B6 (cs) | 1999-03-19 | 2013-01-30 | Smithkline Beecham Biologicals S. A. | Imunogenní prostredek |
AU757334B2 (en) * | 1999-03-30 | 2003-02-13 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
JP2003509452A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ポリオキシエチレンアルキルエーテル又はエステル及び少なくとも一つのノニオン界面活性剤を含有するアジュバント |
EP1221971A2 (en) | 1999-09-24 | 2002-07-17 | SmithKline Beecham Biologics SA | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
AU783118B2 (en) | 1999-09-27 | 2005-09-29 | Coley Pharmaceutical Gmbh | Methods related to immunostimulatory nucleic acid-induced interferon |
ATE336502T1 (de) | 2000-04-07 | 2006-09-15 | Univ Leeds | Hepatitis b kernprotein fusionsproteine |
CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
CA2413546C (en) | 2000-06-22 | 2011-06-14 | Celltech Pharmaceuticals Limited | Modification of hepatitis b core antigen |
EP1304947A1 (en) | 2000-07-15 | 2003-05-02 | Lighthouse Display International Limited | Shelf edge display fittings |
AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US6887472B2 (en) | 2000-08-30 | 2005-05-03 | Pfizer Inc. | Anti-IgE vaccines |
GB0026334D0 (en) | 2000-10-27 | 2000-12-13 | Smithkline Beecham Biolog | Vaccine |
US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
WO2003102165A2 (en) | 2002-02-21 | 2003-12-11 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
CN1599623B (zh) * | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | 免疫刺激物向病毒样颗粒内的包装:制备方法与用途 |
WO2003024480A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
GB0209878D0 (en) | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
CU22983A1 (es) * | 2002-05-08 | 2004-09-09 | Inst Finlay | Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas |
JP4726483B2 (ja) | 2002-07-17 | 2011-07-20 | サイトス バイオテクノロジー アーゲー | 分子抗原アレイ |
ATE546156T1 (de) | 2002-12-10 | 2012-03-15 | Sanofi Pasteur Biologics Co | Stabilisierte immunogene chimäre hbc-partikel |
KR20050115913A (ko) * | 2003-03-26 | 2005-12-08 | 사이토스 바이오테크놀로지 아게 | Melan―a 펩티드 유사체-바이러스-양-입자컨쥬게이트 |
JP2008507474A (ja) | 2004-02-02 | 2008-03-13 | タノックス インコーポレイテッド | 新規のIgEエピトープの同定 |
EP1781325A2 (en) | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
EP1924279A2 (en) * | 2005-09-07 | 2008-05-28 | The Secretary of State for Defence | Adjuvanted vaccine |
JP5473336B2 (ja) | 2006-02-15 | 2014-04-16 | アディウタイド・ファーマスーティカルズ・ゲーエムベーハー | オリゴヌクレオチドの処方に関する組成物および方法 |
US20080166785A1 (en) | 2006-08-16 | 2008-07-10 | Monica Sala-Schaeffer | Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use |
AR065921A1 (es) | 2007-04-02 | 2009-07-08 | Amgen Fremont Inc | Anticuerpos anti-ige |
US20100203083A1 (en) * | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
ES2893464T3 (es) | 2016-06-23 | 2022-02-09 | Ripples Ltd | Procedimiento y aparato para imprimir en una bebida |
-
2009
- 2009-12-04 EP EP20140195370 patent/EP2865389A1/en not_active Withdrawn
- 2009-12-04 CN CN200980149635.5A patent/CN102245198B/zh not_active Expired - Fee Related
- 2009-12-04 MX MX2013006964A patent/MX337723B/es unknown
- 2009-12-04 KR KR1020157012347A patent/KR101634058B1/ko active IP Right Grant
- 2009-12-04 SG SG2012088373A patent/SG186611A1/en unknown
- 2009-12-04 WO PCT/IB2009/055508 patent/WO2010067286A2/en active Application Filing
- 2009-12-04 JP JP2011540292A patent/JP5209800B2/ja not_active Expired - Fee Related
- 2009-12-04 PE PE2014000753A patent/PE20142330A1/es not_active Application Discontinuation
- 2009-12-04 RU RU2011121043/10A patent/RU2495049C2/ru not_active IP Right Cessation
- 2009-12-04 BR BRPI0922561-7A patent/BRPI0922561A2/pt not_active IP Right Cessation
- 2009-12-04 AU AU2009325950A patent/AU2009325950B2/en not_active Ceased
- 2009-12-04 DK DK09793590.2T patent/DK2376108T3/en active
- 2009-12-04 PE PE2011001186A patent/PE20110891A1/es not_active Application Discontinuation
- 2009-12-04 SG SG10201400388QA patent/SG10201400388QA/en unknown
- 2009-12-04 NZ NZ592977A patent/NZ592977A/xx not_active IP Right Cessation
- 2009-12-04 CA CA2744754A patent/CA2744754A1/en not_active Abandoned
- 2009-12-04 KR KR1020117015895A patent/KR101413844B1/ko active IP Right Grant
- 2009-12-04 KR KR1020137003578A patent/KR101644221B1/ko active IP Right Grant
- 2009-12-04 EP EP09793590.2A patent/EP2376108B1/en not_active Not-in-force
- 2009-12-04 MX MX2011006077A patent/MX2011006077A/es active IP Right Grant
- 2009-12-04 ES ES09793590.2T patent/ES2622562T3/es active Active
- 2009-12-04 NZ NZ604186A patent/NZ604186A/en not_active IP Right Cessation
- 2009-12-07 AR ARP090104737A patent/AR074505A1/es unknown
- 2009-12-08 TW TW098141914A patent/TWI387463B/zh not_active IP Right Cessation
- 2009-12-09 US US12/634,336 patent/US8298547B2/en not_active Expired - Fee Related
-
2011
- 2011-05-19 IL IL213029A patent/IL213029A0/en unknown
- 2011-06-01 ZA ZA2011/04072A patent/ZA201104072B/en unknown
- 2011-06-10 CO CO11072267A patent/CO6561830A2/es not_active Application Discontinuation
-
2012
- 2012-04-24 HK HK12104022.0A patent/HK1163511A1/zh not_active IP Right Cessation
- 2012-08-01 US US13/564,103 patent/US8475801B2/en not_active Expired - Fee Related
- 2012-08-08 JP JP2012175784A patent/JP5367137B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-29 US US13/904,432 patent/US9216229B2/en not_active Expired - Fee Related
- 2013-08-12 JP JP2013167494A patent/JP5964280B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-02 JP JP2016039991A patent/JP2016164156A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR074505A1 (es) | Vacuna de peptido ch3 de ige. inmunogeno. procedimiento. vector de expresion. celula huesped. | |
PE20120817A1 (es) | Peptidos tau antigenicos y usos de los mismos | |
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
ES2562456T3 (es) | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes | |
RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
PE20011217A1 (es) | Composicion farmaceutica para modulacion inmunologica y preparacion de vacunas | |
BRPI0417689A (pt) | método para conjugar um imonógeno de peptìdeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivìduo mamìfero, e, uso do conjugado | |
CA2713879A1 (en) | Self-assembling peptide nanoparticles useful as vaccines | |
JP2012511322A5 (es) | ||
WO2011115483A1 (en) | Peptides, conjugates and method for increasing immunogenicity of a vaccine | |
IL278418B2 (en) | A vaccine | |
JP2015519313A5 (es) | ||
KR20140127827A (ko) | H3n2, h2n2, 및 b 인플루엔자 바이러스에 대한 계산적으로 최적화된 넓게 반응하는 항원 | |
PE20150356A1 (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
RU2015141214A (ru) | Вакцины против Chlamydia sp. | |
US20230172869A1 (en) | A nano-enabled vaccination approach for coronavirus disease (covid-19) and other viral diseases | |
RU2017135038A (ru) | Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток | |
ES2351489T3 (es) | Vacunas mejoradas. | |
US9156889B2 (en) | Drug transporter permeating blood-brain barrier, peptide and use thereof | |
PE20231506A1 (es) | Peptidos y combinaciones de peptidos para su uso en inmunoterapia contra una infeccion por sars-cov-2 (covid-19) | |
Gunay et al. | Peptide aggregation induced immunogenic rupture (PAIIR) | |
ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
PE20090163A1 (es) | CONJUGADOS DE PEPTIDOS ANTIFUSOGENICOS Y POLIPEPTIDOS DERIVADOS DE LA CABEZA GLOBULAR DEL FACTOR DEL COMPLEMENTO C1q | |
BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
Soleimani Roudi et al. | Vaccine adjuvants: Past, current and future |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |